Podcasts about Genomic Health

HLTH '24: 23andMe On the second episode recorded live at HLTH in Las Vegas, Jared speaks with Dr. Noura Abul-Husn, VP of Genomic Health at 23andMe. Noura shares an impressive list of ways that genetic profiles can lead consumers to a more preventive state of health, including many that you might not be aware of.  All that, plus the Flava of the Week about the changing dynamics between physicians and patients. How should we process new research from YouGov about doctor-patient relationships, and how can those insights inform the way we design and build consumer experiences?  Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Join us for the 580th episode of the Business Elevation Show, entitled 10x Your Impact, where I sit down with two remarkable leaders who are not only close friends but also valued members of my Elevation Collective—a community where wise, heartfelt leaders connect, support one another, and collaborate to contribute to a better world. Wendy Keller, a publishing powerhouse and messaging expert, has sold over 2,000 book deals worldwide, including multiple New York Times bestsellers. Through Keller Media, she helps visionaries connect with their ideal audiences and build powerful platforms through speaking, social media, and more. Gene Early, an entrepreneurial leader and co-founder of Genomic Health, Inc., brings a wealth of experience in developing talent, fostering trans-formative organisational cultures, and aligning values for impactful change. With a PhD in leadership and organisational development, Gene has worked with global startups and corporates, pioneering innovative approaches in leadership and NLP. Together, we will explore their unique perspectives on how to elevate your message, lead with purpose, and achieve extraordinary results. Whether you're an aspiring author, a leader in transition, or someone seeking to make a greater impact in your field, this conversation will be packed with actionable insights to help you 10x your contribution. Don't miss this powerful and heartfelt dialogue with friends and leaders who share a deep commitment to making a difference in the world.

In this episode of The Med-Tech Talent Lab, we dive into the complex world of Laboratory Developed Tests (LDTs) with Julie Ballard, a clinical laboratory expert with over 25 years of experience in operations, quality systems, and regulatory compliance. Julie shares her journey from working at Stanford Health Care to leading roles in startups like GRAIL, Genomic Health, and Guardant.We unpack the implications of the FDA's groundbreaking LDT ruling, discussing its potential impact on patient care, lab operations, and the broader industry. Julie explains the distinctions between LDTs and FDA-approved tests, the challenges labs face in adapting to the new regulations, and the critical steps they should take now to stay compliant.Julie also sheds light on how these changes create opportunities for talent in regulatory, quality, and consulting roles, offering insights into how labs can navigate this regulatory rollercoaster.Don't miss this expert analysis on one of the hottest topics in clinical labs today!Connect with Julie: https://www.linkedin.com/in/julieballardcarrotclinical/Learn more about Carrot Clinical: https://www.carrotclinical.com/

Host Justin Barnes records live at HLTH 2024 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. On this episode hear Megan Shea, VP, Strategy, Ecosystem & Acceleration for Care Transformation & Innovation with HCA Healthcare and Dr. Noura Abul-Husn, VP of Genomic Health, 23andMe. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Christopher Chambers, MD Guest: Adam H. Buchanan, MS, MPH Since multi-cancer early detection (MCED) testing is a new technology, there's been some discussion in the field about the impact it may have on patients, especially in terms of potential psychological harm like anxiety related to positive test results and false positive test results. Joining Dr. Charles Turck to discuss findings from a recent qualitative survey and the DETECT-A study focusing on how MCED testing may impact patient anxiety are Dr. Christopher Chambers and Mr. Adam Buchanan. Dr. Chambers is a Professor and Director of Clinical Trials at Thomas Jefferson University in Philadelphia, and Mr. Buchanan is an Associate Professor and Chair of the Department of Genomic Health at Geisinger in Danville, Pennsylvania.

Professor and Director Emeritus of Geisinger's Department of Genomic Health, Dr. Marc S. Williams, addresses the current shortcomings of EHR systems in the genomics age, barriers faced in expanding EHR systems to be compatible with genomic information, the role of EHRs in advancing genomic medicine, and ethical, legal, and social implications involved in incorporating genomic information into EHRs.

Gene Early engages at the interface of leadership and organizational development, catalyzing individual and organizational transformation. His work globally with CEOs, senior leaders, and Board members spans the for-profit and not-for-profit sectors.    As a senior advisor in Leaders' Quest, Gene has led learning journeys for over twenty years on four continents with senior executives from multi-nationals committed to integrating purpose and performance. When Covid hit, he pivoted from his primary work with Leaders' Quest to establish a virtual coaching and consulting practice including work with multiple senior executives globally.   In addition to these assignments, he presently is coaching the CEO and the President of 100 Coaches Agency, a talent organization birthed by Marshall Goldsmith and Scott Osman that curates and connects senior coaches with Fortune 50-100 CEOs and senior executives in the US and abroad. He also has led the collaboration of a globally sourced program exploring the development of 10x Mindset and Action. His most recent writing includes 100 posts on the subject of 10x Mindset which can be found at his LinkedIn site.   Previously, he co-founded Genomic Health, a Silicon Valley molecular diagnostic company that produced the first genomic based, breast cancer diagnostic test. In addition, he was Vice-Chancellor of Operations at the University of the Nations-Kona, the original resource campus for this global university with branch campuses in over 600 locations. While living in Copenhagen, he co-founded the first NLP (Neuro-Linguistic Programming) Institute in Europe to train professionals in sophisticated communication skills and helped develop NLP institutes in six European countries. During this time, he also worked with CEOs in the Academy of Chief Executives (UK) as a strategic thinking partner in executive development. His PhD is in leadership and organizational development.   Connect with Business Leaders Network www.businessleadersnetworking.com    grow@businessleadersnetworking.com

JCO PO author Dr. Eric Klein shares insights into his JCO PO article, “Performance of a Cell-Free DNA-Based Multi-Cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancers” Host Dr. Rafeh Naqash and Dr. Klein discuss how a multi-cancer detection test may facilitate workup and stratification of cancer risk in symptomatic individuals. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.   Today, we are excited to be joined by Dr. Eric Klein, Emirates Professor and Chair at the Glickman Urological and Kidney Institute at the Cleveland Clinic Lerner College of Medicine. Dr. Klein is also a distinguished scientist at Grail and author of the JCO Precision Oncology article titled "Performance of a Cell-free DNA-based Multi-cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancer."   Our guest's disclosures will be linked in the transcript.  For the sake of our conversation today, we'll refer to each other using our first names. It's great to have you here today, Eric, and welcome to our podcast.  Dr. Eric Klein: Thanks, Rafeh. I'm happy to be here. Dr. Rafeh Naqash: So today, we're going to try to delve into this very interesting paper. We've had a couple of very interesting podcasts on liquid biopsies, or plan to have a few more. And this is a different aspect of liquid biopsy assessment, and the context here is early cancer detection. Now, the story as it starts, is based on the methylation profile of cancer. Can you tell us, for the sake of our listeners, as we have a very broad audience ranging from trainees to community academic oncologists, what do you understand by methylation profile on a cancer? Dr. Eric Klein: Sure. Happy to start with that. There are lots of cancer signals in the blood. Cancer cells secrete or otherwise supply the bloodstream with DNA that has methylation signals that are specific to cancer. That's a hallmark of cancer-specific mutations. You can look at chromosome fragments, you can look at proteins and mRNA and exosomes and that sort of thing. In Grail's development study, we focused on using methylation because that, as I mentioned, is a fundamental process. A fundamental property of cancer cells is altered methylation. And in our original development studies, that was the strongest signal, the one that allowed us to have the lowest limit of detection when cancer was present, and the one that allowed us to have the best predictive accuracy for the cancer signal origin. Some people think about that as predicting the tumor origin or the tumor type. And that's the basis of Grail's assay, a pan-cancer methylation profile. Dr. Rafeh Naqash: Excellent. And now to understand some of the methodology that you used here, before we go into the details because there's a lot of sensitivity and specificity obviously associated with any cancer detection test, and you want a high sensitivity and specificity. And the idea here is that this would help in triaging patients appropriately using this non-invasive tool. Could you tell us the patient population that you were trying to enroll in this study? And I think there is, again, background to other studies that you have done using the Grail test. Could you put that into context of this specific study?  Dr. Eric Klein: Sure. The population in this particular publication was from substudy 3 of a much bigger study called the Circulating Cell-free Genome Atlas, or CCGA. That was a discovery, refinement, and validation study of this methylation-based signal. And in total, all three substudies together was about 15,000 people, and it was a case-control study. About 10,000 of the individuals enrolled had cancer and about 5000 were not known to have cancer and served as controls. In the first part of the study, substudy 1 of CCGA, we simply asked the question: In individuals with known cancer, could we detect a methylation-based signal? And the answer was ‘yes'. The second question was: In patients not known to have cancer, did we not see a signal? And by and large, the answer was ‘yes'. The second substudy was a refinement and validation of the original methylation-based test. And then this study, what we refer to colloquially as CCGA3, or substudy 3 of CCGA, was the final validation that underlies the methylation assay that is currently on the market.   So, in CCGA3, we determined what the performance characteristics of this test were in a case-control fashion, and what we found, importantly, was that the specificity was very high, at 99.5%, which means the false-positive rate is only half a percent. We found that the overall sensitivity for detecting cancer varied by stage, but when you included all stages 1 to 4, the overall sensitivity for detecting known cancers was about 51%. We found that the ability of this methylation-based test to predict the correct cancer signal origin was right around 90%. And finally, the final performance characteristic was really important, which is the positive predictive value. So in individuals who had a positive signal detected, the positive predictive value was 43%, which compares very favorably to existing screening tests, all of which are below 10%.  That was the background, and the development there was focused on eventually developing a test that will screen the general population, the asymptomatic population, at risk for developing cancer. This is a subset of CCGA3, or the substudy 3 of CCGA, where we looked at the performance characteristics of this test in individuals who had symptoms that could possibly be due to cancer and individuals who had underlying medical conditions that could result in a false positive, and individuals in particular over age 65, because the risk of cancer goes up over age 65. Dr. Rafeh Naqash: Thank you for explaining that. So, again, going to some of the finer details in this study, you mentioned some very important numbers here, 99%, 63%, or something in that range for sensitivity and specificity. Could you explain a little more on that based on the cancer types? As you mentioned, stage 4, when I read the paper, has more true positives likely based on or related to how much cell-free DNA is released in the tumor. The tumor burden may be playing a role there. Could you explain that a little more for our listeners? Dr. Eric Klein: A cancer that sheds cell-free DNA into the bloodstream is more likely to be aggressive, and that's been shown in multiple different studies using multiple different platforms. And the reason for that is that the ability to shed cell-free DNA into the bloodstream goes along with biologic processes that we know are related to tumor aggressiveness. So that's a higher mitotic rate, it's neovascularization or the angiogenic switch, it's the ability to be an invasive cancer. And so the fact that you can detect cell-free DNA in the bloodstream implies some degree of biologic aggressiveness, which is not to say that tumors that shed cell-free DNA into the bloodstream are not curable. They are, in fact, curable at the same rate as cancers in people who are not tested for cell-free DNA. We know that for sure. It's just a signal that is there for us to exploit for the detection of cancers in asymptomatic individuals. And the hope is when we screen the general population, the general asymptomatic population for cancer, as we do with mammography and colonoscopy and PSA and so forth, that we can detect cancers at earlier stages, when they are far easier to cure. So I mentioned in CCGA3 that the overall sensitivity across all stages for detecting the presence of known cancers was 51%. That varied from about 16% for stage 1 cancers to 40% for stage 2 cancers to over 80 and 90% for stage 3 and 4 cancers. Dr. Rafeh Naqash: Right. And again, to provide more background to this, what we've come to understand gradually, as you mentioned, is that shedding is an important event in cancer trajectory. Do you think detection of cancers that are likely positive, driver mutation positive, have a lesser tendency to shed and maybe resulting in lesser tendency to earlier detection also, or is that not something that's true?  Dr. Eric Klein: No, I don't think it has anything to do with the presence of driver mutations. The methylation signal that we see is a reflection of the perturbation of methylation in normal cells. So normal cells turn genes on and off using methylation. That's well known. Cancer cells exploit that biologic process of methylation by - in a gross oversimplification, but in a way that makes it understandable - they use methylation to turn off all the genes that prevent cell growth and turn on all the genes that allow cells to proliferate and get all these other biologic properties that make them invasive and so forth. So it's really important to understand that the test that was used in this study and that was developed in CCGA3 measures a shared cancer signal across multiple different cancer types. In CCGA3, we were able to detect more than 50 different individual kinds of cancers. It's a shared cancer signal that is fundamental to the biology of cancers, not just a specific cancer, but cancers.  Dr. Rafeh Naqash: I see. I think what I was trying to say, basically was, when we do liquid biopsies in the regular standard of care clinic, and you're trying to assess VAFs or variant allele frequencies for a certain mutation, you tend to see some of these BRAFs or EGFRs that are very low VAF, and the data that I've seen is that you treat irrespective of the low VAF, if it's a driving mutation process. If your VAF is 0.1%, you still treat it with a targeted inhibitor. The context that I was trying to put into this is it all depends on shedding. So this liquid biopsy that we currently use, whether other platforms that are out there, if you're not shedding as much cell-free DNA or circulating tumor DNA, you're probably not going to catch that subclone or clone that is a driver. So, does that play a role in your test also? If you have, let's say, a lung cancer that is an EGFR stage 4, if the shedding is low, following a general conceptual context that these driver mutation-positive tumors do have less shedding in general than the non-driver mutation-positive, would you think that would somehow impact the detection using your test or your approach? Dr. Eric Klein: So, generically speaking, any test that looks for a cancer signal in blood is going to have a lower limit of detection. So there are analytic variables that make it such that, if you have extremely low levels of cell-free DNA or your other target shed into the blood, it's not going to be detected by the test. That's an analytical issue. Having said that, it's important to distinguish the fact that this test that we're developing isn't really a liquid biopsy. A liquid biopsy, really, if you think about it, is on patients who have known cancer, and you're doing a biopsy of the blood to determine if you can see a signal in the blood. This test has been developed to screen asymptomatic individuals who are at elevated risk of cancer, who actually may not have cancer. So we don't really view it as a liquid biopsy. But conceptually, you are correct that every test is going to have an analytical lower limit of detection so that not every tumor that sheds minuscule amounts of cell-free DNA will be detected. But that's not really relevant to this particular paper, I would say. It's not really relevant to the performance characteristics that we saw in this population. Dr. Rafeh Naqash: Understood. Thank you for differentiating the usual liquid biopsy approach that we use currently in the clinic, and this approach, which is meant more for detection in asymptomatic individuals.  Going to some of the results, could you highlight some of the interesting findings that you had in this paper as far as performance is concerned? Dr. Eric Klein: Sure. Let me put it in a clinical context because we were just discussing asymptomatic individuals. That's what the test is ultimately meant for - screening asymptomatic individuals. But a common problem in oncology is this: patients present to primary care physicians with vague or nonspecific symptoms. Someone with COPD, for example, who presents with a cough, the cough could be due to the COPD, but if they have an underlying lung cancer, the cough could also be due to the lung cancer. Or someone presents with GI symptoms, could be related to cancer, or it could be related to a whole host of other things. And so there is a challenge for primary care physicians to sort out who might have cancer and who does not, particularly if they present with vague symptoms. In fact, most cancer diagnoses in the United States and Great Britain are actually found by primary care providers.   In this paper, we looked retrospectively, after the fact, in CCGA3, the case-control study that we did, to see how this methylation-based test performed in individuals who had symptoms that could be associated with cancer, or could be due to cancer, or might not be, might be due to other things. What we found was that the performance characteristics were as good or better in this symptomatic population, where the physician is facing a diagnostic dilemma, as they were in the asymptomatic population. This is really important, specificity false negative rate across all the patients in the study was the same as it was in CCGA3. It was 99.5%. Again, the false positive rate was only 0.5%. We found, however, that overall sensitivity was better in the symptomatic population, and it was 64% instead of, or as compared to 43% in the asymptomatic population. That is not surprising because some patients who present with symptoms are more likely to have cancer.   We also looked at a subset of patients who had GI cancers because that's a very, very common presenting symptom in primary care practice, and this test performs exceptionally well for detecting GI cancers. We found that the overall sensitivity was 84%. Finally, and importantly, in terms of the clinical utility of a blood-based test to detect cancer and direct a diagnostic workup, what we call the clinical signal origin accuracy - the likelihood or prediction that a positive signal was related to a particular tumor type - overall accuracy in this population was 90%. So if you had a cancer signal detected and you had a clinical signal of origin assigned to it, let's say, the test came back with cancer signal detected, the CSO prediction was GI cancer, the overall accuracy in actually finding a GI cancer was 90%. Actually, it was a little higher for GI cancers, but overall, for all cancers, it was 90%. Dr. Rafeh Naqash: You mentioned that GI cancers had a very high sensitivity, around 84% or so. Is that, again, related to the tumor shedding compared to some other tumor types?  Dr. Eric Klein: Yes, there is a broad range of shedding across tumor types. So if you look at our data from CCGA, cancers like thyroid, prostate, and kidney do not shed a lot of cell-free DNA into the bloodstream, whereas GI cancers, hematologic malignancies, ovarian and pancreatic cancers shed much more cell-free DNA, and therefore their sensitivity for detection of those cancers is better.  Dr. Rafeh Naqash: What would be the alternate approach? Your sensitivity here is 64%, which is pretty good, but it's not perfect. So the patients who potentially would be missed using this test, what would be the alternate approach capturing those patients also and hopefully avoiding a missed cancer diagnosis?  Dr. Eric Klein: Well, it would be whatever the standard workup is that a primary care physician orders for someone who has vague symptoms. So, he idea here was to develop this, what we call a diagnostic aid for cancer detection in the symptomatic population. The idea here is to make the workups more efficient and to lend a greater degree of certainty as to what the diagnostic pathway ought to be. So, if you have a patient with vague symptoms and you're not sure if they are due to cancer or not, you might order a pretty broad diagnostic evaluation that might not end up finding cancer. In fact, if you take all the patients in a primary care setting, only about 7% of those individuals have cancer. Whereas, if you have a blood test that has a sensitivity of 64% and a positive predictive value of 75%, and you did that blood test early in the diagnostic workup and it was positive, you can do a much more tailored and perhaps a more efficient evaluation in speeding the diagnostic resolution.  Dr. Rafeh Naqash: As you mentioned, perhaps avoid unnecessary testing, which adds to the overall cost burden in the healthcare field.   Dr. Eric Klein: Correct. This was tested in another study called SYMPLIFY, which was done in a similar population of patients as this study - symptomatic patients presenting with vague symptoms or GI symptoms or weight loss, fatigue, those sorts of things, to primary care practice in the UK. And that was a prospective study. And the performance characteristics were very similar to what we saw in this study, although the overall positive predictive value in that study was 75% if you look at all cancers. And that would be very useful to a primary care physician and a patient to know what the likelihood of their having cancer is at the time they present or within a few days of presenting. Dr. Rafeh Naqash: Absolutely. And perhaps, to complement this approach with some of the other diagnostic approaches, maybe the possibility of detecting cancer earlier increases. So this is likely complementary and not necessarily the one-stop-shop. Dr. Eric Klein: It's important to understand that even in the symptomatic population, this is a screening test. And so, like all screening tests, if you have a positive mammogram that shows a nodule, you need to have a diagnostic workup to prove whether or not you have cancer. This blood test does not make the diagnosis of cancer; it simply helps direct a diagnostic evaluation that's necessary to confirm whether or not cancer is present or absent. That's true for both the asymptomatic and symptomatic populations. Dr. Rafeh Naqash: Could you tell us a little bit more about the CSO prediction in the general context of oncology and NGS, or the whole transcriptome sequencing that we do these days? We often see on a report that says,“What is the likely tumor of origin?” if you have an unclear primary. Can you explain that in the context of the approach that you guys use for CSO prediction? How does it differ from methylation versus mRNA prediction of tumor of origin or cell of origin?  Dr. Eric Klein: Methylation has a rich signal in it, and it can distinguish cancer cells from a non-cancer signal, and using a second algorithm, specific methylation patterns that are specific to given lineages can identify lung cancer versus colon cancer versus liver cancer.  Dr. Rafeh Naqash: Understood. Do you see this as becoming an approach that could be used, using, for example, urine or other sources that we can easily acquire versus blood? Dr. Eric Klein: Possibly. There is a lot of work in the field looking at urine-based markers for cancers, particularly, obviously, urologic cancers. And so there are already some products on the market made by other companies using methylation and other specific mutation patterns, for example, in urine to detect bladder cancer and to determine bladder cancer aggressiveness. It is an area of active investigation.  Dr. Rafeh Naqash: This is definitely an exciting field, and the way the entire field of liquid biopsies in general is moving as it's detecting cancers or identifying mutations, and then implementing appropriate approaches, whether it is more screening or more treatment and all the drugs, etc.  Are there any other interesting future approaches that you guys are planning as part of this paradigm shift that I envision will hopefully happen in the next few years?  Dr. Eric Klein: Yes, as a company, Grail is focused on using this methylation-based technology across the entire cancer spectrum. So that's screening asymptomatic individuals, it's helping to direct diagnostic workups in individuals who present with symptoms to primary care practice, and also in the post-diagnostic space and all the possible uses there. So the detection of minimal residual disease and the decision on whether or not additional treatment is necessary, predicting response to particular therapeutic agents, or even choosing the correct therapeutic agents. All of that is under development. Dr. Rafeh Naqash: Definitely exciting. Now, the last portion of this podcast is specifically meant to highlight your career and know a little bit more about you. Could you tell us about your career trajectory and how you shifted focus towards a biomarker-driven approach?  Dr. Eric Klein: Sure. Biomarkers have been a part of my career for a long time. I am trained as a urologic oncologist and did my residency in urology at the Cleveland Clinic and a fellowship at Sloan Kettering. At the dawn of the molecular biology era, the lab I worked in bought one of the very first PerkinElmer RT PCR machines for $5,000. It took up a whole desktop. I got very interested in genomic science at that time. So I spent well over 30 years practicing urologic oncology at the Cleveland Clinic, primarily focusing on prostate cancer. In the course of my career, I had the opportunity to work on a number of blood-based, urine, and tissue-based biomarkers. I have always been interested in understanding how our ability to measure molecules in blood and urine can help improve patient outcomes either through a streamlined diagnostic process or understanding of the biology of the disease better, picking the appropriate therapy, and so forth.  In the course of that, I worked with someone at a company called Genomic Health in developing  a biopsy-based RT PCR gene expression assay that helped select men for active surveillance. That individual subsequently joined Grail and he came knocking on my door in 2016 when Grail was just getting started to tell me about this exciting new technology. He said, “This isn't about urologic cancers in particular, but would you be interested in helping us accrue patients for this big clinical trial we're doing, CCGA, and determine if this technology would be useful in some way in helping patients.” And being the curious individual that I am, I said, “Sure.” And so I helped accrue lots of patients to CCGA. The results were shared, and I was quite excited by them and continued to work with the company on other studies, including PATHFINDER and some others, and eventually became a consultant for them.  When I reached what I thought was the end of my clinical career by choice, I decided to step away from clinical practice, I had the opportunity to join Grail as a scientist, and that's where it's been. And what I would say, in the big picture, is this: as a surgeon, I was able to help a lot of patients on an individual basis. So I did about 10,000 major cancer operations in my career. So I helped those 10,000 people. As an academician, I was able to make certain observations and publish them in a way that taught people about different kinds of surgical techniques and how they may work better, and so I was able to expand my impact beyond the patients that I actually touched.  When I heard about and understood what Grail was trying to do, I thought, “Wow, if we could develop a screening test that detects lots of cancers that we don't screen for - about 70% of all cancer deaths in the US are from cancers that we have no screening tests for - and if the screening population in the United States, individuals between ages 50 and 79, that's how CMS defined screening populations, well over 100 million a year, if this works, think about the impact that that could have.” That is really why I got excited about it. It fit my scientific interest, and I could see the big picture.  Dr. Rafeh Naqash: Thank you for giving us some insights about your personal career. It is definitely a very interesting topic. I learned a lot, and hopefully, our listeners will find it equally interesting. Thank you again for being here today.  Dr. Eric Klein: My pleasure. Thank you for having me. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to rate and review this podcast, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and inform. It is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   The guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not reflect the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.        

Developments in precision medicine have led to a paradigm shift in the management of advanced thyroid cancer. The ESMO Guidelines Committee recently developed a new clinical practice guideline on the use of systemic therapy in this setting. This episode offers guideline insights into the applications recently approved therapies that have been approved by the FDA and/or the EMA, including cabozantinib, selpercatinib, pralsetinib, and entrectinib. It also provides data updates of previously approved therapies and how guidelines have been adapted accordingly. To answer questions on the 2022 ESMO Clinical Practice Guideline update, we have invited Dr. Ahmad Awada to join us. He is Head of the Oncology Medicine Department at Jules Bordet Cancer Institute Brussels, Belgium. Target Audience: Oncologists, pathologists and other HCPs involved in the management of advanced thyroid cancer, with a focus on community practitioners. Learning objectives: After completing this educational activity, learners will be able to: Recall thyroid RET and TRK fusion-positive cancer diagnosis and relevant genomic testing guidelines, and identify ways to adapt the guidelines to local settings Discuss precision medicine and new technologies, including liquid biopsy Review the organization of care and strategies for more efficient care delivery Funding information: This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in collaboration with an independent steering committee; Eli Lilly had no influence on the content of this educational activity. Disclosures Dr. Ahmad Awada declares the following financial relationships from the past 24 months: Speaker fees: Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Genomic Health, Ipsen, Leo Pharma, Eli Lilly, Merck, MSD, Novartis, Pfizer, and Seattle Genetics. Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion. Discussion of Off-Label, Investigational, or Experimental Drug Use: N/A

Company culture is a fundamental part of every organization and has the power to determine long-term viability. Today's guest, Gene Early, is an accomplished entrepreneur who co-founded Genomic Health, a Silicon Valley molecular diagnostic company and trailblazer in personalized medicine. Gene was also the first to bring the globally recognized Neuro-Linguistic Programming process to Europe. … The post A Conversation with Gene Early, PhD on Vision, Company Culture, and Listening to God (Episode # 412) first appeared on TRANSLEADERSHIP, INC®.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Laney K. Jones, PharmD, MPH Patients with familial hypercholesterolemia (FH) are at an increased risk of developing coronary heart disease at a young age. So what's on the horizon for using implementation science strategies in treating patients with FH? Learn more about implementation science as Dr. Mary Katherine Cheeley discusses this with Dr. Laney Jones, Associate Professor at Geisinger's Department of Genomic Health.

In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio's top headlines from the meeting. Virginia G. Kaklamani, MD, DSc, professor of medicine in the division of hematology/oncology at UT Health San Antonio and leader of the breast cancer program at UT Health San Antonio MD Anderson Cancer Center, reviews an abstract presentation on the impact of cyclin-dependent kinase 4/6 inhibitor therapy in patients with advanced breast cancer :00 Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School, discusses a study on trastuzumab-deruxtecan and its response rate in patients with early breast cancer 5:00 Sara A. Hurvitz, MD, FACP, medical oncologist at UCLA Health, Santa Monica Medical Center, associate professor at David Geffen School of Medicine at UCLA, medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, and director of the breast cancer clinical trials program at UCLA, examines trastuzumab-deruxtecan's effect on patients with breast cancer who were previously treated with trastuzumab and a taxane. 10:00 Read the full coverage here: Longer CDK 4/6 inhibitor therapy enhances elacestrant benefit in metastatic breast cancer Elacestrant extends PFS among certain women with metastatic breast cancer Trastuzumab deruxtecan ‘new gold standard' in second line for breast cancer subset Ribociclib regimen may be superior to chemotherapy in advanced breast cancer Breast cancer specialist receives lecture award Genomic assay may predict ovarian function suppression benefit in breast cancer subset Disclosures: Bardia reports research funding from or consultant/advisory roles with AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Immunomedics/Gilead Sciences, Merck, Novartis, Pfizer, Radius Health and Sanofi. Hurvitz reports honoraria from Daichi Sankyo and research funding to her institution from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX Therapeutics, Daiichi Sankyo, Dantari, Dignitana, Eli Lilly, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, MacroGenics, Novartis, OBI Pharma, Orinoco Pharmaceuticals, Pfizer, Phoenix Molecular Designs, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Samumed, Sanofi, Seagen and Zymeworks. She also reports her spouse is a shareholder/stockholder in Ideal Implant. Kaklamani reports honoraria from, consultant/advisory roles with, speakers bureau roles with or other relationships with AstraZeneca, Daiichi Sankyo, Genentech, Genomic Health, Gilead Sciences, Novartis, Pfizer and Puma Biotechnology. Please see the abstract for all other researchers' relevant financial disclosures.

Dr. Noura Abul-Husn is the VP of Genomic Health, and Amy Sturm the Director of Population Health Genomics at 23andMe. With over 13 million customers, 23andMe has built a database that can provide customized and personalized genetic information to individuals that can indicate health predispositions. This kind of information can lead to strategies to reduce the risk of diseases, manage diseases more appropriately, and even prevent diseases. Noura explains, "Well, 23andMe has been delivering results that could lead to critical healthcare decisions, as you said, for a long time now. And the way people are using that today is typically to bring that information to their trusted healthcare provider to find out what next steps they ought to take based on that information. It could be information that indicates they're at a higher risk for cancer, for example, or for high cholesterol. I think in most cases, we do deliver, from the 23andMe side, information about what that result means for the person, for their health, for their potential risks. And then, they can take action based on that and based on shared decision-making, hopefully, with their healthcare providers." Amy elaborates, "All doctors want to do the best thing for their patients, but they are honestly limited in many ways. Time, potential lack of reimbursement for having a genetic counseling type conversation, lack of education, and ongoing education to make sure that they are remaining cutting-edge in any genetics or genetics expertise. That's why we're really excited about the acquisition of Lemonade Health to build out genomic healthcare more broadly under 23andMe. As Noura said, 23andMe has been giving back really important health-related genomic risk results for years that really do need to be taken seriously to prevent diseases like heart disease and cancer." #23andMe #DNATest #GeneticTesting #WelcomeToYou #PrecisionMedicine 23andMe.com Download the transcript here

Dr. Noura Abul-Husn is the VP of Genomic Health, and Amy Sturm the Director of Population Health Genomics at 23andMe. With over 13 million customers, 23andMe has built a database that can provide customized and personalized genetic information to individuals that can indicate health predispositions. This kind of information can lead to strategies to reduce the risk of diseases, manage diseases more appropriately, and even prevent diseases. Noura explains, "Well, 23andMe has been delivering results that could lead to critical healthcare decisions, as you said, for a long time now. And the way people are using that today is typically to bring that information to their trusted healthcare provider to find out what next steps they ought to take based on that information. It could be information that indicates they're at a higher risk for cancer, for example, or for high cholesterol. I think in most cases, we do deliver, from the 23andMe side, information about what that result means for the person, for their health, for their potential risks. And then, they can take action based on that and based on shared decision-making, hopefully, with their healthcare providers." Amy elaborates, "All doctors want to do the best thing for their patients, but they are honestly limited in many ways. Time, potential lack of reimbursement for having a genetic counseling type conversation, lack of education, and ongoing education to make sure that they are remaining cutting-edge in any genetics or genetics expertise. That's why we're really excited about the acquisition of Lemonade Health to build out genomic healthcare more broadly under 23andMe. As Noura said, 23andMe has been giving back really important health-related genomic risk results for years that really do need to be taken seriously to prevent diseases like heart disease and cancer." #23andMe #DNATest #GeneticTesting #WelcomeToYou #PrecisionMedicine 23andMe.com Listen to the podcast here

Noura Abul-Husn got her MD and PhD from Mt Sinai in NYC, where she later served as the first clinical director of the Institute for Genomic Health and Chief of Genomic Medicine. Today, she is Vice President for Genomic Health at 23andMe. She joins us here on the Beagle today to discuss the state of translational efforts in genomic medicine and look at some of the barriers to the integration of genetics into routine clinical care.

The Cadex Genomics mission and passion is to improve the lives of cancer patients. They have developed a novel, blood-based assays for patients with cancer. Over the past several years they have been working diligently to bring their first product to patients and the physicians who serve these patients. They are currently developing a new product called Alibrex, which is a blood-based assay that allows physicians to detect, in real-time, if the disease of their stage IV cancer patients is progressing. Alibrex is currently at the clinical stage and will be available commercially in 2023. The team members have successful track records commercializing molecular diagnostics for oncology at companies including Genomic Health (now part of Exact Sciences), Castle Biosciences and Veracyte. Science and clinical team members are affiliated with the University of New Orleans, Tulane University and the University of California at San Francisco (UCSF). Independent board directors include the Chief Legal and Regulatory Officer for 23 and Me. 

On today's episode Dr. David Kelly is joined by Nick Leventis, senior healthcare analyst for the Innovators strategy at J.P. Morgan Asset Management, to discuss the genomic health revolution. Healthcare spending now amounts to almost 18% of GDP and chronic conditions are on the rise while baby boomers are just beginning to retire. The need for high quality care is becoming more and more important. Genomics, or the study of genes, is making it possible to predict, diagnose, and treat diseases more precisely and personally than ever before. This technology has been key in the creation of a viable and dynamic Covid-19 vaccine, but it has also heralded advancements in sequencing and machine learning, liquid biopsy, proteomics, etc.

The computing world has come a long way in less than 100 years. Since Alan Turing introduced his paper ‘Computing Machinery and Intelligence' in 1950, we have not only achieved the ‘Turing Test' of Artificial Intelligence, but exceeded it. This episode takes a look at Digital Pathology and the prospects of Artificial Intelligence particularly in relation to Anatomical Pathology. Our special guest is Dr Joseph Anderson Dr Joseph Anderson Bio Connect on LinkedIn  Dr. Joseph Anderson, the host of Digital Pathology Today, is a consultant to early stage and mature companies in the digital pathology and molecular diagnostics space. Previously, he oversaw the clinical pathology group at Genomic Health as the Oncotype Dx Breast Cancer Assay grew to a volume of over half a million tests. He was also involved in the development of new products, including assays for DCIS, Colon Cancer and one of the first commercially available liquid biopsies. He served the College of American Pathologists on the Molecular Oncology Committee, with responsibility for proficiency testing in biomarkers for lung cancer in the United States and across the world and as a member of the House of Delegates representing the State of California. He has served on several working groups and committees for the American Medical Association for CPT coding and reimbursement and assessment of new technologies such as next generation sequencing. Upon graduating from the University of Minnesota Medical School, Dr. Anderson completed residency in Anatomic and Clinical Pathology at Rush University, fellowship in Oncologic Pathology at Fox Chase Cancer Center and post-doctoral training in Molecular Diagnostics at UCSF. He initially worked in private practice, credentialed at 17 various hospitals and surgery centers. Digital pathology Today Link: https://www.digitalpathologytoday.com Digital Pathology Today™ is your podcast all about the world of digital pathology.      See omnystudio.com/listener for privacy information.

** Thanks for downloading this episode. If you'd like to stay in touch with our continuing story, Season 2 continues at This Medical Life, in which Dr Travis Brown continues his exploration of diseases and our approaches to treatment from history to the modern day. Have a look in your podcast app now for This Medical Life, and hit subscribe so you never miss an episode ** The computing world has come a long way in less than 100 years. Since Alan Turing introduced his paper ‘Computing Machinery and Intelligence' in 1950, we have not only achieved the ‘Turing Test' of Artificial Intelligence, but exceeded it. This episode takes a look at Digital Pathology and the prospects of Artificial Intelligence particularly in relation to Anatomical Pathology. Our special guest is Dr Joseph Anderson   Dr Joseph Anderson BioConnect on LinkedIn  Dr. Joseph Anderson, the host of Digital Pathology Today, is a consultant to early stage and mature companies in the digital pathology and molecular diagnostics space.Previously, he oversaw the clinical pathology group at Genomic Health as the Oncotype Dx Breast Cancer Assay grew to a volume of over half a million tests. He was also involved in the development of new products, including assays for DCIS, Colon Cancer and one of the first commercially available liquid biopsies.He served the College of American Pathologists on the Molecular Oncology Committee, with responsibility for proficiency testing in biomarkers for lung cancer in the United States and across the world and as a member of the House of Delegates representing the State of California. He has served on several working groups and committees for the American Medical Association for CPT coding and reimbursement and assessment of new technologies such as next generation sequencing.Upon graduating from the University of Minnesota Medical School, Dr. Anderson completed residency in Anatomic and Clinical Pathology at Rush University, fellowship in Oncologic Pathology at Fox Chase Cancer Center and post-doctoral training in Molecular Diagnostics at UCSF. He initially worked in private practice, credentialed at 17 various hospitals and surgery centers. Digital pathology Today Link: https://www.digitalpathologytoday.comDigital Pathology Today™ is your podcast all about the world of digital pathology.   See omnystudio.com/listener for privacy information.

What do you do when you feel ‘stuck' or that you aren't meeting your potential, or just upset and angry with people around you? All the answers to moving forward productively in such scenarios lies within. Listen to this episode to take away some tools that might help you. In this episode we celebrate Gene Early. Gene is a Leadership and Organisational Development expert. He works as a strategic advisor to global leaders, entrepreneurs and non - profits across Asia, Australia, Europe and the United States. He works with these leaders to develop transformational leadership, strong organisational cultures as well as helps them to broaden and deepen their impact. As a partner in Leaders' Quest, he has led learning journeys with senior executives from multinationals interested in integrating purpose and performance since 2001. He co - founded Genomic Health, a molecular diagnostic company in Silicon Valley that produced the first genomic based breast cancer diagnostic test. He also co founded the first NLP - Neuro Linguistic Programming Institute in Europe. He has a PhD in Leadership and Organisational Development and has authored numerous articles, books and eBooks. In this episode we learn about his journey that led him to this work, we talk about choices we make, getting closer to our essential selves and much more. A hugely insightful person. You can check out some of his articles on his LinkedIn profile or start with one article on Leading with your best self here. Note - This conversation was recorded over Zoom. In case of any podcast requirements of consulting, production, post production, write in to kanishka@disorientedpenguin.com. For any feedback or suggestions for this podcastm write to anewkindofcelebrity@gmail.com #coaching #selfawareness #transformation #potential #leadership #introspection --- Send in a voice message: https://podcasters.spotify.com/pod/show/anewkindofcelebrity/message

The field of MedTech uses the latest technology to address medical challenges and find new ways to transform patient care. The industry is filled with groundbreaking experts paving the way to a better and healthier future— transforming patient care and saving countless lives. In this exciting new podcast, Andrew Cleeland invites listeners to tune in as he interviews MedTech professionals about their journeys to success and how their innovative contributions are disrupting and transforming the industry.    Andrew Cleeland welcomes Ginger Graham as the guest in this pilot episode. Ginger Graham is the owner of Ginger & Baker, and Chairman at Clovis Oncology, Inc. She is the former President and CEO of Amylin Pharmaceuticals and also serves on the boards of directors for Walgreen Co., Walgreens Boots Alliance, and several other biotech companies. She joins Andrew Cleeland to share her story - her successes, her failures, her mistakes, and the challenges she overcame. Additionally, she shares lessons she learned along the way and impactful advice that she applied to her personal and professional life.    One such lesson is about maximizing your full potential. We all have a gift in life that is uniquely ours, and the onus is on us to use it to our full ability. We have a responsibility to ourselves and everyone who has supported us to be our best selves.   Resources Ginger and Baker Fogarty Innovation Youtube   Biography: Ginger began her healthcare career at Eli Lilly, the starting point for many pivotal leaders in our industry. Her career highlights include roles as CEO of Advanced Cardiovascular Systems (ACS); group chairman for the Office of the President at Guidant Corporation as the company launched the world's leading stent platform; and president and CEO of Amylin Pharmaceuticals, a biotech company that she took public.   She currently serves on numerous boards, including Walgreens Boots Alliance, Genomic Health and Elcelyx Therapeutics; and she co-chairs the Scientific Council of the University of Colorado Center for Women's Health Research. She has come full circle as a faculty member at Harvard Business School; an accomplished writer, she has written for the Harvard Business Review and serves on the University of Arkansas Chancellor's Board of Advisors. Ginger is the recipient of numerous awards, including being listed in Pharma VOICE's “100 of the Most Inspiring People,” among many others. True to her philanthropic spirit, in her spare time she coaches first-time CEOs in leadership strategy and organization building.   SHOW LESS    

Chris Yoko, CEO of Yoko Co., and his team exclusively support heroic nonprofit organizations in their quest to change the world.  They set a BHAG at the beginning of 2020 to positively affect the lives of 100 million people through their clients.  The result:  They reached 127 million people in 2020. Chris has worked with some of the planet’s largest and most impactful brands, such as Ritz Carlton, Pampers, and Living Social.  He’s equally adept at positively impacting smaller brands, like FHI360, Life Sherpa, and Genomic Health. In this podcast we explore The Yoko Manifesto.  It explains Chris’ belief that mankind must successfully continue our evolution and expand our knowledge.  The path is for people to navigate seven major transitions during our lifetimes. Listen to this podcast to learn more.

Returning guest and study author, Steve Shak, Chief Medical Officer at Exact Sciences discusses results presented at SABCS (San Antonio Breast Cancer Symposium) from the Phase 3 RxPONDER (Rx for Positive Node, Endocrine Responsive) study, one of the largest randomized, prospective clinical trials in women with node-positive, hormone receptor-positive (HR+), HER2- early-stage breast cancer. Dr. Steve Shak is the Chief Medical Officer for Exact Sciences. Joining the company in 2019 upon the closing of the Genomic Health / Exact Sciences combination, his key responsibilities include leading strategy for the company’s clinical development plans, building relationships with key leaders and institutions in the cancer community, and ensuring the voice of patients and physicians are heard at all levels of the organization. Before serving as Chief Medical Officer, he was the Co-Founder, Chief Medical Officer, and Chief Scientific Officer at Genomic Health, driving Oncotype DX assay development in breast, prostate and colon cancer. Before then, he was the Research Director and Staff Clinical Scientist at Genentech, leading the clinical team in the development of the targeted breast cancer drug Herceptin®, and the research team in the discovery of the cystic fibrosis drug Pulmozyme®. He also taught as an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Dr. Shak received his medical degree from New York University School of Medicine and his formal post-doctoral training at Bellevue Hospital and the University of California, San Francisco. He has a bachelor’s degree from Amherst College in Massachusetts.

There’s no overstating how far we have come since 2000 in the fledgling science of genomics, but at times it has seemed that our ability to amass information has far outstripped our ability to make that information matter by improving healthcare. As extraordinary as the technology is, it cannot get it out of the computer and into clinical practice. Enter Eimear Kenny and Noura Abul-Husn, respectively Founding Director and Clinical Director of the Institute for Genomic Health at the Icahn School of Medicine at Mount Sinai in New York.

This episode we are exploring medical interpreting in genetic counseling and other areas of healthcare. Joining me are Genetic Counselor Nina Harkavy and Interpreter Lorraine Way. Nina is a prenatal genetic counselor at Columbia University. She graduated from the John Hopkins University/ NHGRI genetic counseling training program. Lorraine is a Spanish Instructor, medical interpreter and the President of Language Way, a language service company. She has a master’s in French from Middlebury College where she also studied Spanish. On This Episode We Discuss:Improved counseling experience speaking in SpanishDifference between translation and interpretation How healthcare providers can alter their communication with non-native English speakersTips for working with interpretersStandard for interpretation especially with family membersMaintaining cultural sensitivity when belief systems may impede the decision-making processConcepts that are challenging to interpret into Spanish and ways to phrase differentlyApproaches to check in with patients about their understandingMiscommunications between healthcare providers and interpreters Handling an interpreter who is not accurately interpreting Training to be a professional interpreterQualities to look for when hiring an interpreter Learn more about Lorraine way business through her website, thelanguageway.comImagine a health record system that’s actually designed for genomics, available in 6 different languages, and complete with pedigree drawing, diagnostic insights and more. Well stop imagining and start using, because PhenoTips is nothing like your EHR, it’s the world’s first Genomic Health record system that captures family history seamlessly, regardless of the language patients are comfortable with. Because clear communication is the root of supportive care. Visit phenotips.com to learn more. Check out our sponsor at PhenoTips.com to learn more. Also sponsoring this episode is Genobank, the first anonymous DNA storage and sharing platform that is completely controlled by you with blockchain technology. Here’s the really cool aspect about Genobank, you can choose who you are sharing your DNA with including researchers. You can be a partner in research by choosing specific institutions who can use your DNA in their research projects. Genobank has officially launch at genobank.io, where you can learn more and purchase a kit. Stay tuned for the next new episode of DNA Today the first week of January. New episodes are released on the first and third Friday of the month. In the meantime, you can listen to over 130 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. See what else we are up to on Twitter, Instagram, Facebook and iTunes. Questions/inquiries can be sent to info@DNApodcast.com.

The National Society of Genetic Counselors (NSGC) hosted its annual conference virtually this past weekend with a new record for attendance. In this special extended installment of DNA Today we are recapping and reflecting on a few sessions from the conference. Thanks to our sponsor for this episode, PhenoTips. Imagine a health record system designed specifically for genomics. Cause let’s be honest, electronic health records are not built for genetics. Now you can stop imagining and start using, because PhenoTips is just this! PhenoTips is the world’s first complete Genomic Health record system with pedigree drawing, standardized symptom capture, diagnostic insights and more, all in one place. Check them out at PhenoTips.com. TimestampsAishwarya Arjunan 1:30-24:20Rebekah Hutchins 25:17-38:50Courtney Studwell 38:50-53:05Ashlyn Enokian 53:05-56:05Presentations Recapped/RecommendedDrawing the line with ECS: When does expanded carrier screening turn into excessive carrier screening? Live Tweet Threads by DNA Today and Aishwarya Arjunan More Than Just Raising Our Voices: Confronting Injustices in Patient Care Beyond common aneuploidies: Expanding existing chromosome testing technologies and subsequent prenatal care Live Tweet Thread by DNA TodayTransfer of Mosaic Embryos following PGT-A: Updates, Ethics, and Implications Live Tweets by DNA Today (1, 2, 3, 4, 5, 6, 7)2020 Janus Lecture: Ovarian Cancer: A Model for Progress in GeneticsPariah or Pioneer? Stories of Expansion Into New and Emerging Genetic Counselor RolesMastering the Art of Advocacy through Media Relations The PanelAishwarya Arjunan, MS, MPH, CGC, CPH graduated with degrees in genetic counseling and public health genetics from the University of Pittsburgh in 2013 and was certified by the American Board of Genetic Counseling in 2014. She currently works at Myriad Women's Health (formerly Counsyl), a women's health genetic testing and genetic counseling company, as the Clinical Product Manager for the Foresight Carrier Screen. Prior to joining Counsyl/Myriad, Aishwarya was a clinical genetic counselor at the Sarnoff Center for Jewish Genetics and Ann & Robert H Lurie Children’s Hospital in the Department of Genetics, Birth Defects, and Metabolism. Within the Northwestern Genetic Counseling Program, Aishwarya is a core faculty member and serves as a thesis advisor/committee member and has participated in the Admissions Committee and Internet Resources Task Force. Aishwarya is actively involved with the National Society of Genetic Counselors (NSGC) as the 2019 co-chair of the Diversity and Inclusion Task Force and incoming Director At Large for the NSGC Board of Directors. She is also involved locally with the Illinois Society of Genetic Professionals (ISGP) and is a past-president of ISGP. At NSGC 2020 she was honored with the Leader in Cultural Advocacy Award. You can follow Aishwarya on Twitter. Rebekah Hutchins, MS, GC is a perinatal genetic counselor. Currently, she practices at Northside Hospital in Atlanta, Georgia and previously in Hawaii Pacific Health in Honolulu, Hawaii. She received her M.S. in Human Genetics from Sarah Lawrence College’s Joan H. Marks Program. Rebekah has always been passionate about social justice and identifying, dissecting and combating health disparities in marginalized communities. Now as a healthcare professional she identifies innovative ways to bridge those gaps in her work. During her time at Sarah Lawrence College, she developed a cultural competency course for genetic counselors which she has presented twice. You can follow Rebekah on Twitter. Courtney Studwell, MS, CGC, MB(ASCP)CM is a licensed certified genetic counselor at Brigham and Women's Hospital, Boston and is also certified as a Technologist in Molecular Biology through the American Society for Clinical Pathology (ASCP). She counsels patients in the CFMRG and participates in the development and management of genetic testing platforms in the CAMD. She earned her master's degree in Genetic Counseling from Boston University School of Medicine and undergraduate degree in Diagnostic Genetic Sciences from University of Connecticut. You can follow Courtney on Twitter. Ashlyn Enokian, MS, GC is a prenatal genetic counselor at High Risk Pregnancy Center in Las Vegas, NV. Her journey into the field of genetic counseling began with advocacy work through Crisis Text Line and Help Pregnancy Crisis Aid. She worked as a genetic counseling assistant in cancer genetics at Saint Joseph Mercy Hospital, pediatric genetics at the University of Michigan, and laboratory genetics at Progenity, Inc. Ashlyn was previously a genetics graphic design intern at My Gene Counsel. Her professional interests include prenatal, ART/fertility, education, and strategies to increase diversity in the field. She earned her B.S. in Biology and a minor in Criminal Justice from Grand Valley State University in 2017. Followed by her M.S. in Human Genetics from Sarah Lawrence College’s Joan H. Marks Program. You can follow Ashlyn on Twitter. Kira Dineen, MS, LCGC, CG(ASCP)CM is a certified prenatal genetic counselor at Maternal Fetal Care, PC in Stamford, CT. Kira also has 10 years of online media experience in digital marketing and podcasting/radio including 5 podcasts. She started her main show “DNA Today: A Genetics Podcast” in 2012 which became a radio show in 2014. The podcast has since produced over 130 episodes interviewing experts in the field. “DNA Today” recently won the People’s Choice Podcast Awards for the Best 2020 Science and Medicine Podcast. Kira is also the host of the PhenoTips Speaker Series, a live webinar interviewing genetic experts attend by over 700 genetic counselors around the globe. She writes a monthly blog series, “Explained By A Genetic Counsellor” for Sano Genetics. Kira was selected and currently serves as a member of the National Society of Genetic Counselors’ Digital Ambassador program (#NSGCGenePool). She received her Diagnostic Genetic Bachelor’s of Science degree at the University of Connecticut and is a certified Cytogenetic Technologist. Kira received her Master’s of Science in Human Genetics at Sarah Lawrence College in New York. You can follow Kira on Twitter. PosterPresentations Conference Tips (Virtual & In-Person)Exhibit hall for networking, free genetics apparel, job board, professional and fun photos.Wear layers because lecture halls are freezing.Lunch sessions are free and sponsored by labs. Prioritize select sessions to attend live, there is too much to do everything and you can watch later on demand until it expires January 15th. Attend a Special Interest Group (SIG), you don’t have to be a member.Follow and join conversations on Twitter (#NSGC20 and #gcchat)Students, job hunt utilizing the job board (in the middle of the exhibit hall) and hand out your resume. If there is a meet up with a specific company/hospital you are interested in working with/at, then go check it out!ResourcesBe sure to check out all these resources mentioned during the episode. JGC Task Force ReportAll the special issuesSign up for the Focus GroupsStay tuned for the next new episode of DNA Today on December 4th. New episodes are released on the first and third Friday of the month (except this week, thanks for waiting!). In the meantime, you can binge over 130 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to info@DNApodcast.com.

Dedicated to bringing genomics to everyday care https://outcomesrocket.health/lisaalderson/2019/09/

By Michael Tetreault, Editor, Concierge Medicine Today & Host, The DocPreneur Leadership Podcast Today we sit down with Dr. Roxana Rhodes MD, a wonderful and compassionate Concierge Medicine Physician serving the Central Austin, Texas area. We also discuss the importance of incorporating Precision Medicine and Genomic Health tools into her practice in today's interview. "The name of the practice reflects my core belief that the best way to achieve lifelong wellness is to form a strong partnership between doctor and patient. To give you some of my background, I grew up a 3rd generation Texas physician, and have always been strongly attracted to the medical profession. My medical training includes an undergraduate degree from Texas A&M, a medical degree from the University of Texas Medical Branch, and residency training with the Yale School of Medicine in Danbury, Connecticut, where I was chief resident." Having been the recipient of years of training, she also believes strongly in her responsibility to mentor the next generation of health providers. Since she is an Assistant Professor for the University of Texas Medical Branch (UTMB), you will almost always see a physician in training at her office. Not only do they get some real world experience but her practice also gains from their knowledge and enthusiasm. She has been honored to receive UTMB's “Top Doc” Award twice in her career. "As an Internist, I am specialized around the treatment of adult disease, including chronic diseases such as diabetes and high blood pressure. Precision Medicine and Genomic Health is integrated into my practice. I offer a range of services including annual physical exams, suturing, ingrown toenail removal, well woman exam, mole removal, ECG, and dermabrasion. We use a state of the art Electronic Medical Records system, and maintain a patient web portal so you can always have access to your records and test results." CONNECT WITH Dr. RHODES Partners in Health, M.D., P.A. 631 West 38th Street, Suite 5 Austin, TX 78705 Phone: 512-453-3542 Fax: 512-453-3555 Email: info@partners-in-health.com https://partners-in-health.com/

Exact Sciences (EXAS) is a diagnostic company offering non-invasive colorectal cancer screening with their flagship product, Cologuard. Today, the company's valuation stands at around $14B and they will need to be aggressive in increasing the product's market share in order to justify this valuation. Recently, they acquired Genomic Health, which will provide them with other sources of revenue. They are also making good progress with a liquid biopsy test for Hepatocellular Carcinoma.Don't forget to like and subscribe! Follow me on twitter @matthewlepoire Email me: matthewlepoire@gmail.com www.breakingbiotech.com biotech #EXAS #cancer Disclaimer: All opinions expressed by Matt in this podcast are solely his opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast.Support Breaking Biotech by donating to their Tip Jar: https://tips.pinecast.com/jar/breaking-biotech

Dedicated to bringing genomics to everyday care https://outcomesrocket.health/lisaalderson/2019/09/

Mr. Anson Tharayanil, a Medical Science Liaison from Genomic Health rejoins Joel Nowak from Cancer ABCs to talk about another test for men diagnosed with low or favorable medium risk prostate cancer, the Oncotype DX Genomic Prostate Score.The test should be used along side the traditional measures we use like biopsy Gleason Grade and scans to help a man decide if he is a good candidate for Active Surveillance (AS) as opposed to having surgical or a radiation intervention. Biopsies only sample 1% of a man's prostate gland, so as a stand alone measure it does not provide us with an accurate understanding of the aggressiveness of a man's prostate cancer. When added to the other measures, we traditionally still fall far short of accurately knowing which prostate cancers need immediate treatment and which can be monitored. Research shows that at least 20% of men who qualify for AS using the traditional measures if they go on and have surgery they find that their cancer is actually a lion in sheep's clothing, or is very dangerous. The Oncotype DX Genomic Prostate Score has been well validated and should automatically be used by any man who is trying to decide if they are a good candidate for Active Surveillance. Support the show (https://www.cancerabcs.org/new-page-2/)

This educational series is supported by independent educational grants from: AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme Episode 3: Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents and Radionuclide Therapy and Bone Health Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents David F. Jarrard, MD Radionuclide Therapy and Bone Health Steve Boorjian, MD CME Available: auau.auanet.org/node/25405 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists. To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/novel-agents-concepts-management-hormone-na%C3%AFve-castrate-resistant-prostate-cancer-webcast-0 This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed. Learning Objectives: Diagnose both non-metastatic and metastatic castrate resistant prostate cancer (nmCRPC, mCRPC) and have a working knowledge of treatments and the proper order for administration. Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy. Analyze the mechanism of action and risks/benefits of using systemic agents in the treatment of nm/mCRPC. Describe the bone-targeted, radiopharmaceutical agent and its sequencing. Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC.

This educational series is supported by independent educational grants from: AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme Episode 2: Setting Up and Managing Advanced Prostate Cancer in the Community Setting: Unique Challenges and the Role of Chemotherapy, Treatment Sequencing and Future Approaches CME Available: https://auau.auanet.org/node/25404 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists. To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/node/24579 Instructional Course Director(s) Danil Makarov, MD photo Danil Makarov, MD New York University School of Medicine Instructional Course Faculty(s) Michael Barry, MD Harvard Medical School Angela Fagerlin, MD Chair, Department of Population Health Sciences Shared Decision Making was recently accepted as the standard of care when counseling patients considering PSA screening by the US Preventative Services Taskforce. Shared Decision Making is also embedded into numerous recently published AUA guidelines (including the localized prostate cancer guideline). In spite of these clear recommendations, Shared Decision Making is not frequently used in clinical practice. We propose a course that would teach the essentials of Shared Decision Making (SDM) to practicing urologists who help patients decide about prostate cancer screening and treatment. The course will go over the latest research documenting the benefits and drawbacks of Shared Decision Making when counseling patients considering PSA screening as well as treatment approaches for incident localized prostate cancer. It will also teach the participants how to practice SDM with their patients and will engage them in group-based role play. At the end of the session, participants will understand how to apply SDM in their practice. Learning Objectives: Explain Shared Decision Making. Discuss the impact of shared decision making on patients and on patient-clinician communication. Describe at least one implementation strategy for using shared decision making in clinical practice. Explain Shared Decision Making techniques in a role playing exercise with other attendees. Apply the knowledge they have gained through role play into their routine practice counseling patients.

In this podcast Anson Tharayanil, a Meical Science Liaison from Genomic Health, Inc. talks with Joel Nowak about their test, the Oncotype DX ARV-7 Nucleus Detect Test for men with castrate resistant metastatic prostate cancer. The test is used to determine if the second line hormone therapies like Xtandi, Zytiga and Erleada will be an effective treatment for men who have the diagnosis of prostate cancer that has left the gland (if they have metastases) and are no longer responding to the first line hormone (ADT) treatments like Lupron, Eligard, Prostap and Casodex. Initially, Anson gives an explanation about what is castrate resistant metastatic prostate cancer so that everyone can clearly understand the disease process that happens as prostate cancer progresses. Afterwards, he describes how the Oncotype DX ARV-7 Nucleus Detect Test works so that you can know if you are a candidate for any of the new second line hormone therapy drugs (Zytiga, Xtandi and Erleada). Anson also describes how it might be possible to re-sensitive some men who have stopped responding to thee drugs. Support the show (https://www.cancerabcs.org/new-page-2/)

This educational series is supported by independent educational grants from: AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme Episode 1: Genetic Testing in Advanced Prostate Cancer and the Identification of High Risk Disease and Initial Management of Biochemical Recurrence CME Available: https://auau.auanet.org/node/25403 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists. To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.

I loved every bit of this conversation.  Chris and I talk about renewable energy, spirituality, fatherhood and how millennials can become better leaders.  If you love this conversation and would love to help support the show, please click here More on Chris: Driven by an indefatigable determination to make the world a better place, Chris is focused on helping people, and the organizations they belong to, pave the road to a more utopian world. He primarily does this by helping these like-minded organizations build and champion themselves using their most powerful asset, their web presence. His career is riddled with helping some of the planet’s largest and most impactful brands, like Ritz Carlton, Pampers, and Living Social. As well as smaller, but no less intentional brands, like FHI360, Life Sherpa, and Genomic Health. His work at Yoko Co alone has positively affected the lives of 37 million people to date. Chris excels at aligning strategy and execution with goals and objectives, solving unusual problems, and helping to create a remarkable experience. His background encompasses a well-rounded mix of media, sales, marketing, and entrepreneurial experience which enables him to understand and assist clients with challenges and needs across multiple departments. Often featured in media, you may have seen him on MSBNC, or in the Washington Post, Forbes, Bloomberg, and Mashable to name a few.    

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/integrating-care-oncology-patients-establishing-multidisciplinary-oncology-clinic-advanced This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting. Participants will have a better understanding of the best timing for referrals to medical oncology with specific examples including hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, role of immunotherapy in advanced bladder and kidney cancer. The integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection will be discussed. An emphasis will be placed on the upcoming expansion of checkpoint inhibitors in urologic malignancies and the changing definitions of disease progression. Learning Objectives: Describe the components of a multidisciplinary urologic cancer cancer and identify the best structure for the practice. Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer. Demonstrate an understanding of advances in genomic testing and personalized medicine for urologic cancers. Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/aua-castration-resistant-prostate-cancer-crpc-guidelines-and-therapeutic-advances-metastatic Instructional Course Director(s) Michael Cookson, MD, MMHC Professor and Chair University of Oklahoma Instructional Course Faculty(s) David Jarrard, MD University of Wisconsin Adam Kibel, MD Brigham Health, Harvard University William Lowrance, MD University of Utah, Huntsman Cancer Institute This course will review the important and newly updated 2018 AUA Guidelines on Castration-Resistant Prostate Cancer. This includes a thorough discussion of new trials and approval of agents for MO non-metastatic nmCRPC. In addition, we will review therapeutic breakthroughs in the management of advanced and metastatic hormone naïve prostate cancer (mHSPPC). Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines. Also, the role of genomic classifiers and genetic testing in the evaluation of CRPC, as well as discuss new developments and future research needs for this topic. The course will showcase clinical scenarios in urological practice and the correct application of the new AUA CRPC guidelines in those instances. This course will be a benefit to practicing urologists, oncologists, advanced practice providers, and residents/fellows preparing for their certification exam and physicians preparing for their re-certification exam. Learning Objectives: Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC Understand the sequencing and indications for active treatment with approved agents in the management of nmCRPC Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice Understand and analyze breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/chemo... Instructional Course Director(s) Costas Lallas, MD Thomas Jefferson University Hospital Instructional Course Faculty(s) Anne Calvaresi, DNP, CRNP Thomas Jefferson University Edouard Trabulsi, MD, FACS Sidney Kimmel Medical College at Thomas Jefferson University Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, prostate, and testis cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a question and answer period. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included. Session objectives will include familiarity with systemic therapy regimens for these malignancies as well as their specific expected outcomes and side effects. Learning Objectives: Describe the standard of care chemotherapy regimens for genitourinary malignancies Recall both historic and newer immunotherapy options in the treatment of genitourinary malignancies, including recently approved checkpoint inhibitors and antibody-drug conjugates. Outline the mechanism of action of common chemotherapy and immunotherapy regimens for genitourinary malignancies. Recognize and manage the adverse events related to these agents. Identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies. List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies.

Prof. Joshua Krieger from Harvard Business School shares his perspectives on some of the challenges and opportunities in commercialization of diagnostic tests and gives us a preview of his business case study on Genomic Health. For more information, please visit https://www.NextGenerationDx.com/Commercialization-Molecular-Diagnostics

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/node/24582 Instructional Course Director(s) Todd Morgan, MD University of Michigan Instructional Course Faculty(s) Leonard Gomella, MD,FACS Professor And Chair Thomas Jefferson University Heather Cheng, MD, PhD University of Washington There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g. PARP inhibition), Urologists are suddenly being confronted with questions surrounding screening guidelines in men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations (present in greater than 10% of men with metastatic disease). This course will cover the state of the art in genetic testing and discuss the practical impact on patient care. Urologists will leave this course with a clear understanding of how to translate these latest scientific advances into their routine clinical practice, improving the care of these men who are at a markedly elevated risk of progression and death from prostate cancer. Learning Objectives: Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.

Mark Hall was diagnosed with metastatic prostate cancer with a PSA of 4,400 and a Gleason Score of 8. Despite these terrible numbers he has been thriving the last four years with an undetectable PSA and a fantastic quality of life!Mark shares his journey, where under the guidance of Dr. Charles (Snuffy) Meyers he went through a heavy regime of hormone therapy treatments as well as the immunotherapy Provenge (sipuleucel-T). Mark has been experiencing a profound four year remission of his probate cancer. Mark attributes his remission to the Provenge treatment as well as Dr. Meyers guidance. The Cancer ABCs podcast program receives support from Genomic Health, which transforms treatment decisions in cancer by delivering clinically actionable diagnostics. Support the show (https://www.cancerabcs.org/new-page-2/)

Genetics vs. Genomics. While these two terms are certainly related to one another, they are also very different, especially when it comes to a cancer diagnosis. On this episode of Frankly Speaking About Cancer, guest host Linda House explores the role genomics play in a cancer diagnosis, from how it impact your diagnosis, to the impact on decision-making and everything in between.

Amid Zand interviews Dr. Richard White of Genomic Health on June 11, 2014. Dr. White will be speaking at the Companion Diagnostics: Technology and Reimbursement track at the Next Generation Dx Summit, August 19-21, in Washington, D.C.

Kim Popovits, President and COO of Genomic Health, Inc., discusses the organizational and technological strategies that have contributed to her success in the biopharmaceutical industry.